Back to Immunity
SupplementPreliminary evidenceImmunity

Schisandra chinensis (Wu Wei Zi)

TCM adaptogenic berry with EMA Traditional Use registration and preliminary RCTs for stress, hepatic enzymes and exercise endurance.

Why

Schisandra chinensis berries ('five-flavour fruit', wu wei zi) hold an EMA HMPC Traditional Use monograph for symptoms of asthenia. Used in TCM as a Qi-tonifying, liver-protecting, and astringent herb. Small modern RCTs and an active mechanistic-research program (Panossian group) support adaptogenic effects on cortisol and exercise capacity. Hepatoprotective evidence is mostly preclinical and Chinese.

How it works

Schisandrins are CYP3A4 inducers and Pgp inhibitors, relevant drug-interaction profile. Modulate the HPA axis and salivary cortisol response to stress in adaptogen models. Hepatic cytochrome induction underlies the proposed hepatoprotective effect.

Expected onset · Fatigue and stress effects over 4–8 weeks

How to take

Dosage

Standardised extract: 500–1,000 mg/day. Dried berry: 1.5–6 g/day. Tincture: 2–4 ml three times daily.

Timing

Morning and early afternoon; can be activating

On the label

EMA-registered traditional herbal medicinal products available in some EU markets. Standardised extract with stated schisandrin content. Avoid bulk-grade berry powder without third-party testing.

Ideal for

Adults with stress-related fatigue exploring TCM-rooted adaptogens; people with mild liver function elevations seeking complementary support under clinical guidance.

Safety

CYP3A4 induction is meaningful, interactions with ciclosporin, tacrolimus, carbamazepine, hormonal contraceptives, statins (effect may vary). Avoid in pregnancy and breastfeeding. Caution in peptic ulcer (astringent/stimulating to gastric secretion at high doses) and epilepsy. Generally well tolerated in trial doses.

Evidence

At a glance

EMA classifies Schisandra fruit at Traditional Use for symptoms of asthenia, based on >30 years of consistent traditional use. Panossian 2008 J Ethnopharmacol summarises the mechanistic adaptogen literature. Modern clinical-trial evidence is sparse; the regulatory anchor is the traditional-use registration. Preliminary evidence, no Cochrane review, EMA HMPC monograph or EFSA-authorised health claim covers this indication; cited RCTs are small or in non-tier-1 journals. Useful as honest reference rather than evidence-grade recommendation.

Limitations

Clinical-trial evidence is largely from small Chinese RCTs in non-tier-1 journals. Mechanistic evidence is stronger than clinical-outcome evidence at the moment.

Where to get it

Shop Schisandra chinensis (Wu Wei Zi) on Amazon

Sponsored · As an Amazon Associate, Healicus earns from qualifying purchases.